BioSpace News Archive

Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic information services, announced that it will report third quarter 2023 financial results on Tuesday, October 24, 2023, before the market opens.

DIMERx, Inc., an advance-stage biopharmaceutical company, today announced that Nikhilesh N. Singh, Ph.D., Co-Founder and Chief Executive Officer, will present at the BIO Investor Forum 2023, being held October 17-18, 2023, in San Francisco.

Adicet Bio, Inc. (Nasdaq: ACET) today announced a poster presentation at the upcoming 2023 International Conference on Molecular Targets and Cancer Therapeutics hosted by the American Association for Cancer Research, the National Cancer Institute, and the European Organisation for Research and Treatment of Cancer to be held in Boston from October 11-15, 2023.

University of Maryland School of Medicine Dean Mark T. Gladwin, MD, and University of Maryland Medical Center President and CEO Bert W. O’Malley, MD, announced that Taofeek K. Owonikoko, MD, PhD, a distinguished physician-scientist with a global reputation in thoracic oncology, has been appointed Executive Director of the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center.

Standard BioTools Inc., driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – and SomaLogic, a leader in data-driven proteomics technology, announced that they have entered into a definitive agreement to combine in an all-stock merger.

Aethlon Medical, Inc. announced that its Board of Directors has approved a 1-for-10 reverse stock split of the Company’s common stock, effective at 5:00 p.m. ET on October 4, 2023.

Aerium Therapeutics Advances Next Generation Antibodies to Protect Immunocompromised Persons Against COVID-19.

Alpine Immune Sciences, Inc. today announced the appointment of Wolfgang Dummer, M.D., Ph.D., to Chief Medical Officer effective October 2, 2023.

New York Blood Center Enterprises and Talaris Therapeutics, Inc. announced NYBCe’s acquisition of commercial-scale cell and gene therapy development and manufacturing facilities, as well as certain technologies and equipment from Talaris in Houston, Texas and Louisville, Kentucky.

Arcturus Therapeutics Holdings Inc. announced today that ARCALIS, Arcturus’ manufacturing joint venture in Japan to support the production of mRNA vaccines and therapeutics, has been selected by the Japanese Ministry of Economy, Trade and Industry to receive additional financial support to construct a DNA template manufacturing facility along with new state-of-the-art equipment.